The U.S. Department of Energy has selected two nuclear reactorsin New Mexico to produce molybdenum-99, the raw material for thecommonly used radioisotope technetium-99m. The move is an importantstep in a long effort by the agency to develop a U.S. source
The U.S. Department of Energy has selected two nuclear reactorsin New Mexico to produce molybdenum-99, the raw material for thecommonly used radioisotope technetium-99m. The move is an importantstep in a long effort by the agency to develop a U.S. source formolybdenum (SCAN 6/7/95).
The DOE hopes the project will provide an alternative to molybdenumdistributed by Canadian radioisotope firm Nordion Internationalof Kanata, Ontario. Nordion provides over 80% of the world's supplyof molybdenum, which is produced at a reactor operated by a Canadiangovernment agency (SCAN 7/17/96).
The DOE this month selected two sites, the Annular Core ResearchReactor and the Hot Cell Facility at Sandia National Laboratoriesin Albuquerque, and the Chemistry and Metallurgy Research Facilityat Los Alamos National Laboratory in Los Alamos, to produce molybdenum.The decision came after completion of an environmental impactstatement earlier this year.
The facilities should begin producing small quantities of molybdenumthis year, with production for medical uses beginning in 1997after Food and Drug Administration approval is granted. The DOEhopes to provide 10% of the U.S. supply of molybdenum next year,and believes the facilities could ultimately meet all of the U.S.needs for the radioisotope.
The DOE said it will encourage the privatization of molybdenumproduction. The New Mexico reactors are intended to ensure a reliablebackup supply of the isotope, and the DOE does not plan to competewith commercial radioisotope suppliers, the agency said.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.